Logan Coy Related postsAn Open-Label, Phase 1/2 Study Evaluating Immunomodulatory AVM0703 in Patients with Lymphoid Malignancies (the OPAL Study)September 11, 2026A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer After Prior ChemotherapySeptember 11, 2026A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Elritercept (KER-050) for Transfusion-Dependent Anemia in Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (RENEW)September 11, 2026 Previous postA Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study of Topical HT-001 for Skin Toxicities Associated with Epidermal Growth Factor Receptor InhibitorNext postA Phase 1/2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Advanced Cancer
